Introduction
============

The majority of cancer-related mortality (as much as 90%) is associated with metastasis [@B1]. Acquisition of cell motility is the initial step in cancer invasion and metastasis, and aberrant regulation of the actin cytoskeleton in cancer cells is a fundamental mechanism enhancing cancer cell motility [@B2], [@B3]. Filopodia are actin-rich, slender projections on the cell surface that play an important role in cell migration. Fascin is an actin-bundling protein in filopodia that maximally cross-links actin filaments into tight bundles to provide filopodia with rigidity [@B4]. It is abundantly expressed in some types of normal cells, including neurons, glial cells, endothelial cells, and antigen-presenting dendritic cells [@B5]. Fascin overexpression is a poor prognostic indicator associated with aggressive clinicopathological features and metastasis in various types of human carcinomas, including breast cancers [@B6].

Breast cancer metastasis suppressor 1 (BRMS1) is a member of the family of metastasis suppressor genes initially discovered to reduce metastatic potential in a breast cancer xenograft model [@B7]. Subsequently it was found to suppress metastasis in other carcinomas, such as ovarian cancer, melanoma, rectal cancer, and non-small cell lung cancer. BRMS1 inhibits metastasis by targeting multiple steps of the metastatic cascade---cell adhesion, invasion, angiogenesis, and cytoskeletal rearrangement- without affecting primary tumor growth [@B8]-[@B12].

A previous study demonstrated that fascin had an inhibitory effect on BRMS1 protein and an inverse correlation with the proteins in breast cancer [@B13]. However, no reported study has examined the relationship between expression patterns of these anti- and pro-metastatic molecules and patient outcome. We investigate expression patterns of fascin and BRMS1 in human breast cancer tissues and assess whether the two combinatorial markers reflect clinicopathological features.

Materials and Methods
=====================

Patient selection and collection of clinicopathological data
------------------------------------------------------------

This study included 183 patients who underwent surgical treatment and were diagnosed with invasive breast cancer at CHA Bundang Medical Center from January 2006 to December 2008. Patients who underwent neoadjuvant chemotherapy before surgical treatment were excluded. Clinical data, including patient age at initial diagnosis, local recurrence, systemic recurrence, and patient survival, were retrieved from electronic medical records. This study was approved by the institutional review board of CHA Bundang Medical Center. Hematoxylin and eosin (H&E)-stained slides of all cases were reviewed by two pathologists (HJ Lee and S Kim). Histological subtypes were classified based on the World Health Organization classification of breast tumors [@B14]. Histological grade was assessed using the Nottingham grading system [@B15]. Tumor stage was based on the 7th American Joint Committee on Cancer (AJCC) criteria [@B16].

Tissue microarray (TMA) construction
------------------------------------

A representative H&E-stained slide was selected for each case, and corresponding spots were marked on the surfaces of the paraffin blocks. Two core tissue biopsies (2 mm in diameter) were taken from each paraffin block and arranged in recipient TMA blocks using a trephine apparatus. A normal breast tissue core was included in each TMA block. Each tissue core was assigned a unique TMA number and linked to a database containing the clinicopathological data.

Immunohistochemical staining and interpretation
-----------------------------------------------

Immunohistochemistry (IHC) staining was performed on the TMA blocks using a mouse monoclonal antibody to fascin (Epitomics, Burlingame, CA, USA; 1:100) and rabbit polyclonal antibody to BRMS1 (Genetex, Irvine, CA, USA; 1:100). Briefly, 4 μm TMA sections were transferred to adhesive slides and dried at 62°C for 30 min. After incubation with primary antibodies, immunodetection was achieved with the addition of biotinylated anti-mouse and rabbit immunoglobulins, followed by peroxidase-labeled streptavidin (a component of a streptavidin-biotin kit), and 3,3\'-diaminobenzidine as the chromogenic substrate. Slides were counterstained with Harris hematoxylin.

All IHC-stained slides were interpreted by two pathologists (HJ Lee and S Kim) under a multiview light microscope. Fascin IHC was scored with reference to the intensity and proportion of cytoplasmic staining of tumor cells as in previous studies [@B17]-[@B19]. The proportion of stained tumor cells (0: 0-5%, 1: 6-25%, 2: 26-50%, 3: 51-75%, or 4: \>75%) and staining intensity (0: no staining, 1: weak, 2: moderate, or 3: strong) were multiplied and defined as negative (0-3) or positive (4-12). Vascular endothelium exhibited strong staining for fascin and served as a positive internal control. Because BRMS1 expression pattern did not show intratumoral heterogeneity, only the staining intensity was considered in determining the BRMS1 expression level as in a previous study [@B20]. Nuclear and cytoplasmic staining intensities of BRMS1 were scored separately (0: no staining, 1: weak, 2: moderate, or 3: strong). We obtained the BRMS1 H score (range: 0-6) by summing the nuclear and cytoplasmic scores. Then we defined BRMS1 expression as negative (BRMS1 H score: 0-2) or positive (BRMS1 H score: 3-6). Normal breast epithelium exhibited strong staining for BRMS1 and served as a positive internal control for BRMS1 expression.

Statistical analysis
--------------------

Data were analyzed using SPSS (ver. 20.0 for Windows; IBM Corp., Armonk, NY, USA). Fisher\'s exact test or the chi-square test was used to compare categorical variables. Student\'s *t* test was used to compare continuous variables (BRMS1 H scores). A *p*-value of \<0.05 indicated statistical significance. Survival analyses were performed using the Kaplan-Meier method with the log-rank test. Multivariate analyses were performed using Cox\'s regression model.

Results
=======

Baseline patient characteristics
--------------------------------

Clinicopathological characteristics of the patients and tumors are summarized in Table [1](#T1){ref-type="table"}. Age at initial diagnosis was classified as \<50 years (62.3%) or ≥50 years (37.7%). Regarding tumor stage distribution, 48.6% and 51.4% of cases presented with pT1 and pT2-3. Lymph node metastasis (pN1-3) was observed in 45.4% of cases. Histological grade was 2 or 3 in 85.3% of cases. Nuclear grade was 2 or 3 in 60.1% of cases. The distribution of intrinsic subtypes was as follows: 101 luminal A (55.2%), 18 luminal B (9.8%), 22 HER2 (12.0%), and 42 TNBC (23.0%). Tumor recurrence, either local or systemic, occurred in 36 patients (19.7%), and death from breast cancer occurred in 26 patients (14.2%). The mean follow-up period was 87 months.

Correlations between fascin expression, clinicopathological features, and BRMS1 status
--------------------------------------------------------------------------------------

Fascin positivity was observed in 33 of 183 patients (18.0%). In analyses of the relationship between fascin status and various clinicopathological parameters (Table [1](#T1){ref-type="table"}), fascin positivity was significantly associated with negative nodal metastasis (*p* = 0.003), higher histological grade (*p* = 0.005), higher nuclear grade (*p* = 0.001), ER negativity (*p* \< 0.001), PR negativity (*p* \< 0.001), HER2 negativity (*p* = 0.018), and triple-negative subtype (*p* \< 0.001). The inverse correlation between fascin and BRMS1 expression is shown in Figure [1](#F1){ref-type="fig"}. Although it was not statistically significant, BRMS1 nuclear expression tended to be negative or weak in fascin^+^ tumors. Negative or weak BRMS1 cytoplasmic expression was observed more frequently in fascin^+^ than in fascin^-^ tumors (*p* = 0.012). A lower BRMS1 H score (0-1) was observed more frequently in fascin^+^ than in fascin^-^ tumors (*p* = 0.031). The mean BRMS1 H score was also significantly lower in fascin^+^ (2.27 ± 1.77) than in fascin^-^ (3.14 ± 1.63) tumors (*p* = 0.008). Stratification of clinicopathological parameters by BRMS1 expression status revealed no statistically significant differences between the BRMS1^+^ and BRMS1^-^ groups (data not shown).

Clinicopathological differences according to fascin and BRMS1 expression
------------------------------------------------------------------------

The distribution according to fascin and BRMS1 staining results was as follows: 51 fascin^-^/ BRMS1^-^, 99 fascin^-^/BRMS1^+^, 18 fascin^+^/BRMS1^-^, and 15 fascin^+^/BRMS1^+^. Compared to the fascin^-^/BRMS1^+^ subgroup, the fascin^+^/BRMS1^-^ subgroup was significantly associated with negative nodal metastasis (*p* = 0.038), higher histological grade (*p* = 0.040), higher nuclear grade (*p* = 0.008), ER negativity (*p* \< 0.001), PR negativity (*p* \< 0.001), and triple-negative subtype (*p* \< 0.001) (Table [2](#T2){ref-type="table"}). The representative cases of fascin^-^/BRMS1^+^ and fascin^+^/BRMS1^-^ tumors are depicted in Figure [2](#F2){ref-type="fig"}.

Survival outcome according to clinicopathological differences and fascin/BRMS1 status
-------------------------------------------------------------------------------------

Univariate analyses of all patients (*n* = 183) revealed that factors associated with shorter disease-free survival (DFS) were nodal metastasis (*p* = 0.005), higher AJCC stage (*p* = 0.002), higher histological grade (*p* = 0.006), and negative or weak BRMS1 cytoplasmic expression (*p* = 0.043). Factors associated with shorter overall survival (OS) were higher T stage (*p* = 0.003), nodal metastasis (*p* = 0.004), higher AJCC stage (*p* \< 0.001), and higher histological grade (*p* = 0.027). Then we performed multivariate Cox regression analyses on the prognostic factors identified in the univariate analyses. In multivariate analyses, nodal metastasis (hazard ratio \[HR\] = 1.811; 95% confidence interval \[CI\] = 0.833-4.201.56; *p* = 0.020) and higher AJCC stage (HR = 2.854; 95% CI = 1.212-4.812; *p* = 0.025) significantly increased the likelihood of tumor recurrence, whereas higher AJCC stage (HR = 3.159; 95% CI = 1.460-6.834; *p* = 0.003) was the only factor that significantly increased the likelihood of patient death (Table [3](#T3){ref-type="table"}).

Survival analyses were also performed, confined to the patients with nodal metastasis (*n* = 117, Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). Fascin positivity was associated with shorter DFS in both univariate (*p* = 0.005) and multivariate (HR = 5.583; 95% CI = 1.318-23.655; *p* = 0.020) analyses. Factors associated with shorter OS were higher T stage (*p* = 0.048), TNBC subtype (*p* = 0.028), fascin positivity (*p* = 0.031), and fascin^+^/BRMS1^-^ subgroup (*p* = 0.041). In multivariate analyses, higher T stage (HR = 5.622; 95% CI = 1.055-29.968; *p* = 0.043) and fascin positivity (HR = 5.869; 95% CI = 1.202-28.662; *p* = 0.029) significantly increased the likelihood of patient death.

Discussion
==========

We evaluated whether expression patterns of fascin and BRMS1 correlate with clinicopathological features and patient outcome in breast cancer. A previous study demonstrated that fascin promoted breast cancer invasion via upregulating NF-κB activity, urokinase-type plasminogen activator (*u*PA), and matrix metalloproteases (MMPs) that are essential to metastasis; in contrast, fascin inhibited the nuclear expression of BRMS1 in breast cancers [@B13]. To assess the importance of the intracellular localization of BRMS1, we separately interpreted the nuclear and cytoplasmic expression of BRMS1. Our results showed that loss of nuclear BRMS1 expression was more frequently observed in fascin^+^ tumors (although this was not statistically significant). Cytoplasmic BRMS1 expression and combined expression levels of nuclear and cytoplasmic BRMS1 (defined as the BRMS1 H score) showed a significant inverse correlation with fascin expression, which reflects the fact that intracellular expression of BRMS1 is downregulated by fascin.

The BMRS1 sequence contains nuclear export and import signals that enable its nucleus-cytoplasm shuttling [@B21]. It is not yet fully understood how the anti-metastatic effects of BRMS1 are influenced by its intracellular localization. Two melanoma studies reported that nuclear expression promoted metastatic capacity, whereas cytoplasmic expression suppressed metastasis and increased DFS [@B9], [@B22]. By contrast, a breast cancer study reported that a shifting of BRMS1 from the nucleus to the cytoplasm was associated with aggressive features, such as a high proliferation index and a trend toward worse OS [@B23]. We found that loss of BRMS1 cytoplasmic expression was associated with shorter DFS, whereas nuclear BRMS1 expression status did not affect patient prognosis.

In this study, fascin positivity was significantly associated with various unfavorable clinicopathological parameters, including higher histological and nuclear grades, hormone receptor negativity, and triple-negative subtypes, as in previous studies [@B17], [@B24]. Such correlations remained when we compared the clinicopathological characteristics of the fascin^-^/BRMS1^+^ and fascin^+^/BRMS1^-^ tumor subgroups. These results may partially explain why breast cancers with these well-known unfavorable clinicopathological features have a higher possibility of metastasis: They are enriched with metastasis-promoting factors and lack metastasis-suppressing factors.

The only unexpected finding was that axillary lymph node metastasis was observed more frequently in fascin^-^ tumors than in fascin^+^ tumors. A few previous studies have found a significant positive correlation between fascin expression and lymph node metastasis [@B25], [@B26], but other studies have failed, as in this study [@B17], [@B24] These inconsistent results are probably due to the fact that various factors besides fascin and BRMS1 contribute to lymph node metastasis under complex interrelationships. Another possible reason may be attributed to the nature of the cohort included in our study. After reviewing the patients\' clinicopathological data, we found that most of the TNBC patients in our cohort were in the early stage without nodal metastasis. This probably weakened the importance of fascin as a prognostic factor; thus, we performed an additional prognosis analysis confined to patients without nodal metastasis. In the node-negative patient group, fascin was a significant independent predictor of shortened DFS and OS. In addition, the fascin^+^/BRMS1^-^ tumor group showed a shorter OS than the fascin^-^/BRMS1^+^ tumor group (although this was not statistically significant in multivariate analyses). These results suggest that the fascin positivity and loss of BRMS1 expression contribute to poor clinical outcomes in node-negative breast cancers that generally show a favorable prognosis. In regions where breast cancer screening is widely available, such as in South Korea, node-negative cases account for a high percentage of all breast cancers. About 60% of Korean breast cancer patients are found to have no lymph node metastasis at the time of initial diagnosis [@B27], [@B28]. Adjuvant systemic chemotherapy decreases the risk of distant metastasis and death in about 30% of patients with node-negative breast cancer, while the remaining 70% do not achieve additional therapeutic benefit from such treatment [@B27]. Therefore, it is important to identify biomarkers that can predict and select the patients who are more likely to benefit from adjuvant chemotherapy. To the best of our knowledge, this study is the first to report that positive expression of fascin and/or expressional loss of BRMS1 may be a critical predictor of a poor prognosis in the patients with node-negative breast cancer. For this reason, staining of these two biomarkers is recommended especially in the node-negative patients.

In conclusion, this is the first reported study to examine expression of fascin and BRMS1, a metastatic promoter and suppressor, in a quite large cohort of breast cancer patients. Our results confirm the inverse correlation between expression of the two markers in breast cancer tissues. Fascin alone or combined with BRMS1 has value as a poor prognostic marker, particularly in node-negative breast cancer patients.
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A comparison of the distribution of BRMS1 expression status between fascin^-^ and fascin^+^ breast cancers. (a) Distribution of nuclear BRMS1 expression, (b) distribution of cytoplasmic BRMS1expression, (c) distribution of low and high BRMS1 H scores, (d) difference in mean BRMS1 H scores.
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![Photomicrographs of representative cases of fascin-/BRMS1+ and fascin+/BRMS1- breast cancers. (a) In contrast to stromal endothelial cells, which are normal internal controls, no fascin staining is observed in tumor cells. BRMS1 is stained in both nucleus and cytoplasm, but nuclear staining intensity is stronger than cytoplasm in this case. (b) Strong cytoplasmic fascin staining is observed in tumor cells, whereas BRMS1 is almost completely disappeared in the nucleus and is stained very faintly only in the cytoplasm](jcav08p3122g003){#F2}

![Kaplan-Meier survival curves analyzed in node-negative patients only. (a) Disease-free survival (DFS) according to fascin status, (b) overall survival (OS) according to fascin status, (c) difference in DFS between fascin^-^/BRMS1^+^ and fascin^+^/BRMS1^-^ patients, (d) difference in OS between fascin^-^/BRMS1^+^ and fascin^+^/BRMS1^-^ patients.](jcav08p3122g004){#F3}
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Correlations between fascin expression and clinicopathological features

  Parameter                Number            Fascin Negative   Fascin Positive   *p*-value    
  ------------------------ ----------------- ----------------- ----------------- ------------ ----------
  Age                      \<50              114 (62.3)        91 (60.7)         23 (69.7)    0.428
                           ≥50               69 (37.7)         59 (39.3)         10 (30.3)    
  Tumor stage              pT1               89 (48.6)         72 (48.0)         17 (51.5)    0\. 848
                           pT2-3             94 (51.4)         78 (52.0)         16 (48.5)    
  Nodal stage              pN0               100 (54.6)        74 (49.3)         26 (78.8)    0\. 003
                           pN1-3             83 (45.4)         76 (50.7)         7 (21.2)     
  AJCC stage               I                 148 (80.9)        118 (79.4)        30 (90.9)    0.142
                           II-III            35 (19.1)         32 (21.3)         3 (9.1)      
  Histologic grade         1                 26 (14.2)         26 (17.3)         0 (0.0)      0.005
                           2/3               157 (85.8)        124 (82.7)        33 (100.0)   
  Nuclear grade            1                 73 (39.9)         68 (45.3)         5 (15.2)     0.001
                           2/3               110 (60.1)        82 (54.7)         28 (84.8)    
  Lymphovasculr invasion   Absent            79 (43.2)         60 (40.0)         19 (57.6)    0.081
                           Present           104 (56.8)        90 (60.0)         14 (42.4)    
  ER                       Positive          117 (63.9)        114 (76.0)        3 (9.1)      \< 0.001
                           Negative          66 (36.1)         36 (24.0)         30 (90.9)    
  PR                       Positive          94 (51.4)         91 (60.7)         3 (9.1)      \<0.001
                           Negative          89 (48.6)         59 (39.3)         30 (90.9)    
  HER2                     Negative          143 (78.1)        112 (74.7)        31 (93.9)    0.018
                           Positive          40 (21.9)         38 (25.3)         2 (6.1)      
  Intrinsic subtype        Luminal A         101 (55.2)        98 (65.3)         3 (9.1)      \<0.001
                           Luminal B         18 (9.8)          18 (12.0)         0 (0.0)      
                           HER2              22 (12.0)         20 (13.3)         2 (6.1)      
                           Triple-negative   42 (23.0)         14 (9.3)          28 (84.8)    
  Tumor recurrence         Yes               36 (19.7)         28 (18.7)         8 (24.2)     0.473
  Patients death           Yes               26 (14.2)         20 (13.3)         6 (18.0)     0.581

###### 

Correlations between combined fascin and BRMS1 expression status and clinicopathological features

  Parameter                Fascin-/BRMS1+    Fascin+/BRMS1-   *p*-value    
  ------------------------ ----------------- ---------------- ------------ ----------
  Age                      \<50              61 (61.6)        13 (72.2)    0.439
                           ≥50               38 (38.4)        5 (27.8)     
  Tumor stage              pT1               49 (49.5)        8 (44.4)     0.800
                           pT2-3             50 (50.5)        10 (55.6)    
  Nodal stage              pN0               49 (49.5)        14 (77.8)    0.038
                           pN1-3             50 (50.5)        4 (22.2)     
  AJCC stage               I                 79 (79.8)        15 (83.3)    1.000
                           II-III            20 (20.2)        3 (16.7)     
  Histologic grade         1                 21 (21.2)        0 (0.0)      0.040
                           2/3               78 (78.8)        18 (100.0)   
  Nuclear grade            1                 44 (44.4)        2 (11.1)     0.008
                           2/3               55 (55.6)        16 (88.9)    
  Lymphovasculr invasion   Absent            40 (40.4)        10 (55.6)    0.302
                           Present           59 (59.6)        8 (44.4)     
  ER                       Positive          75 (75.8)        0 (0.0)      \<0.001
                           Negative          24 (24.2)        18 (100.0)   
  PR                       Positive          59 (59.6)        0 (0.0)      \<0.001
                           Negative          40 (40.4)        18 (100.0)   
  HER2                     Negative          73 (73.7)        17 (94.4)    0.069
                           Positive          26 (26.3)        1 (5.6)      
  Intrinsic subtype        Luminal A         63 (63.6)        0 (0.0)      \< 0.001
                           Luminal B         13 (13.1)        0 (0.0)      
                           HER2              13 (13.1)        1 (5.6)      
                           Triple-negative   10 (10.1)        17 (94.4)    
  Tumor recurrence         Present           83 (83.8)        16 (88.9)    0.738
  Patients death           Present           12 (12.1)        3 (16.7)     0.700

###### 

Univariate and multivariate analyses of disease-free and overall survival

  Parameters                                           Disease free survival   Overall survival                                                 
  ---------------------------------------------------- ----------------------- ---------------------- ------- ---------- ---------------------- -------
  **Analysis in all patients (*n* = 183)**                                                                                                      
  Age (\<50 vs. ≥50)                                   0.802                                                  0.249                             
  T stage (pT1 vs. pT2-3)                              0.098                                                  0.003      2.047 (0.759-5.520)    0.157
  N stage (pN0 vs. pN1-3)                              0.005                   1.811 (0.833-4.201)    0.020   0.004      1.613 (0.563-4.619)    0.373
  AJCC stage (I vs. II-III)                            0.002                   2.854 (1.212-4.812)    0.025   \< 0.001   3.159 (1.460-6.834)    0.003
  Histologic grade (1 vs. 2-3)                         0.006                   1.332 (0.926-3.278)    0.186   0.027      1.533 (0.823-3.554)    0.974
  Nuclear grade (1 vs. 2-3)                            0.055                                                  0.103                             
  Intrinsic subtype (non-TNBC vs. TNBC)                0.074                                                  0.589                             
  Fascin (Negative vs. Positive)                       0.317                                                  0.345                             
  BRMS1-nuc (Moderate/Strong vs. Negative/Weak)        0.988                                                  0.415                             
  BRMS1-cyt (Moderate/Strong vs. Negative/Weak)        0.043                   1.875 (0.949-3.702)    0.070   0.145                             
  BRMS1-H score (3-6 vs. 0-2)                          0.769                                                  0.492                             
  Fascin^-^/BRMS1^+^ vs. Fascin^+^/BRMS1^-^            0.698                                                  0.430                             
  **Analysis in node-negative patients (*n* = 117)**                                                                                            
  Age (\<50 vs. ≥50)                                   0.463                                                  0.335                             
  T stage (pT1 vs. pT2-3)                              0.258                                                  0.048      5.622 (1.055-29.968)   0.043
  Histologic grade (1 vs. 2-3)                         0.050                                                  0.155                             
  Nuclear grade (1 vs. 2-3)                            0.136                                                  0.549                             
  Intrinsic subtype (non-TNBC vs. TNBC)                0.125                                                  0.028      2.030 (0.127-32.417)   0.617
  Fascin (Negative vs. Positive)                       0.005                   5.583 (1.318-23.655)   0.020   0.031      5.869 (1.202-28.662)   0.029
  BRMS1-nuc (Moderate/Strong vs. Negative/Weak)        0.121                                                  0.145                             
  BRMS1-cyt (Moderate/Strong vs. Negative/Weak)        0.470                                                  0.619                             
  BRMS1-H score (3-6 vs. 0-2)                          0.321                                                  0.717                             
  Fascin^-^/BRMS1^+^ vs. Fascin^+^/BRMS1^-^            0.240                                                  0.041      1.185 (0.151-9.294)    0.871

*nuc* nuclear, *cyt* cytoplasmic, *HR* hazard ratio, *CI* confidence interval
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